Leflunomide Ab (Leflunomide)

Lefuno­mide blocks the enzyme dihydroorotate dehydrogenase, a key step in de novo pyrimidine synthesis. By limiting pyrimidine production, the drug suppresses the proliferation of activated lymphocytes, thereby dampening the immune response that drives joint inflammation in arthritis.

The dosing regimen for Leflunomide Ab is determined by the prescribing physician based on the patient’s clinical status, renal and hepatic function, and other individual factors. The prescriber will set the appropriate dose and any necessary loading or maintenance schedule.

The safety of lefuno­mide in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and to discuss alternative therapies with a healthcare professional. Women of child‑bearing potential should use effective contraception while on treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lefuno­mide is an oral synthetic DMARD that differs from biologic agents such as TNF‑α inhibitors. It offers the convenience of once‑daily oral dosing and a distinct mechanism targeting pyrimidine synthesis, whereas biologics act on cytokine pathways. Choice of therapy depends on disease severity, patient preference and safety considerations.

Leflunomide Ab should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Leflunomide Ab is taken orally, usually as a tablet swallowed with water. The exact timing and whether it should be taken with food are determined by the prescribing clinician, who will provide instructions tailored to the individual patient.

Serious risks include hepatotoxicity, which can lead to severe liver injury, and immunosuppression‑related infections. Blood dyscrasias such as neutropenia or anemia may also occur. Patients should be monitored regularly for liver enzymes, complete blood counts and signs of infection.

Leflunomide Ab is contraindicated in patients with severe hepatic impairment, active serious infections, or known hypersensitivity to lefuno­mide. Caution is also advised for individuals with pre‑existing hypertension, pregnancy, or those taking interacting medications listed under major drug interactions.